NCT06732323View on ClinicalTrials.gov

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

504

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

July 31, 2028

Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
DRUG

ESG401

IV infusion on day 1,8, and 15 of each 28 day cycle

DRUG

Investigator's Choice Chemotherapy

Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin

Trial Locations (1)

Unknown

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY